Cue Biopharma PE Ratio 2016-2021 | CUE

Current and historical p/e ratio for Cue Biopharma (CUE) from 2016 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cue Biopharma PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Cue Biopharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 14.91 0.00
2021-06-30 11.65 $-1.45 0.00
2021-03-31 12.20 $-1.50 0.00
2020-12-31 12.51 $-1.57 0.00
2020-09-30 15.05 $-1.57 0.00
2020-06-30 24.51 $-1.54 0.00
2020-03-31 14.19 $-1.62 0.00
2019-12-31 15.88 $-1.68 0.00
2019-09-30 8.43 $-1.89 0.00
2019-06-30 8.99 $-2.20 0.00
2019-03-31 7.73 $-2.10 0.00
2018-12-31 4.70 $-1.93 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.446B $0.003B
Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71